The Possible Role of Medical

Ozone in Angiogenesis

Shadia Barakat*, Aziza Seif-El Nasr*; Nabil Abdel-Maksoud, Faika El-Ebiary** Hanaa Amer***,

Amal Zeghloul***& Sahar Thabet*.

Department of *Physiology & Department of **Histology, Department of Clinical Pathology****, Faculty of Medicine Ainshams University, Cairo Egypt; Department Industrial & Occupational Medicine of , Faculty of Medicine, Cairo University, Egypt.

Introduction

Angiogenesis

- is a progressive multistage and multifactorial vascular remodeling cascade process
 - [Carmeliat & Collen, 1997].
- is characterized by tight regulation both spatially and temporally
 - [Cross Claesson- Welsh, 2001 & Oettgen et al., 2001].

Angiogenesis

 Mainly induces formation of new capillaries from already present ones to improve tissue oxygenation

[Cao et al., 2001]

 The capillary density is an important determinant of tissue O₂ supply in the mammalian skeletal muscle

[Annex et al., 1999].

Material & Methods

- To elucidate if medical ozone is able to induce angiogenesis, we used three different doses (75, 40 & 4µg O₃ / ml O₂) in white albino rats by i.p. injection. Angiogenesis was assessed in both <u>skeletal</u> and <u>cardiac muscle</u> at the end of the study using morphometric methods:
- Capillary density (cap. dens.,) & number of muscle fibers per field were counted, the ratio of cap. dens.
 / m. fib. (C / F) was calculated.
- Perimeter of m. f. s was measured.

Our data collectively are in favor of:

 Occurrence of endogenous induction of angiogenesis in both cardiac and skeletal muscle by medical O_3 in the three doses used. The "smallest dose with longest duration" group was the most efficient and physiologic.

C/F soleus m.	Control	Small dose	MOG. GOSE	Large dose
Mean	0.1011	0.2900	0.2771	0.2567
St. Dev.	0.0072	0.0189	0.0170	0.0163
P1		<0.	001	
P2		P<0.001	P<0.001	P<0.001
Cap. dens. Soleus m. (no / mm ²)	Control	Small dose	Mod. dose	Large dose
Mean	535.7908	679.4647	660.6840	837.3858
St. Dev.	32.6494	36.1843	34.8657	20.3072
P1		<0.	001	
P2		P<0.001	P<0.001	P<0.001
Perimeter soleus m. (μ m)	Control	Small dose	Mod. Dose	Large dose
Mean	118.8450	122.6583	139.4017	105.6833
St. Dev	2.0848	6.6676	17.0286	5.3618
P1		<0.	001	
P2		NS	0.001	0.027









C/F cardiac m.	Control	Small dose	Mod. dose	Large dose
Mean	0.0270	0.0504	0.0689	0.0522
St. Dev.	0.0048	0.0117	0.0105	0.0441
P1	< 0.001			
P2		<0.001	<0.001	0.001
Cap. dens. cardiac m. (no / mm ²)	Control	Small dose	Mod. Dose	Large dose
Mean	184.0741	266.6497	383.9159	296.2773
St. Dev.	27.6356	62.4683	52.3630	39.5879
P1		<0.	001	
P2		<0.001	<0.001	<0.001
Perimeter cardiac m. (μ m)	Control	Small dose	Mod. Dose	Large dose
Mean	39.9350	48.2320	57.5167	51.0522
St. Dev	4.7540	2.4313	5.6831	4.9769
P1		<0.	001	
P2		<0.001	<0.001	<0.001









RBC (millions/mm ³)	Control	Small dose	Mod. dose	Large dose
Mean	6.2330	7.0233	6.6013	5.8050
St. Dev.	0.3366	1.4404	0.1501	0.9645
P1	0.047			
P2		0.060	NS	NS

HGB (gm/dl)	Control	Small dose	Mod. dose	Large dose
Mean	12.3200	12.8167	12.1500	10.6625
St. Dev.	0.3225	0.8277	0.2268	1.8118
P1	P< 0.001			
P2		NS	NS	0.001

HCT (%)	Control	Small dose	Mod. dose	Large dose
Mean	38.6500	42.2667	38.0125	35.0500
St. Dev.	1.0255	4.8412	1.0494	3.8619
P1	P< 0.001			
P2		0.016	NS	0.030
MCV (fl)	Control	Small dose	Mod.dose	Large dose
Mean	61.0300	57.9167	57.9750	66.6500
St. Dev.	0.7025	2.4954	1.8053	9.8901
P1		0.(002	
P2		NS	NS	0.019

Eosinophiis %	Control	Small dose	MOG. GOSE	Large dose
Mean	1.8000	3.5000	1.7500	1.6250
St. Dev.	0.9189	1.7321	0.2500	0.7440
P1				
P2		0.002	NS	NS
Basophils %	Control	Small dose	Mod. dose	Large dose
Mean	0.5000	0.0000	0.0000	0.000
St. Dev.	0.5774	0.0000	0.000	0.000
P1		<0.	001	
P2		< 0.001	< 0. 001	< 0.001
BMI (gm/cm²)	Conteol	Small dose	Mod. dose	Large dose
Mean	0.5071	0.6158	0.4818	0.5200
St. Dev	0.0341	0.2714	0.0479	0.0245
P1		Ν	S	
P2		0.040	NS	NS

WBC (10 ³ /mm ³)	Control	Small dose	Mod. dose	Large dose
Mean	5.6400	6.5583	4.6125	11.5313
St. Dev.	1.2474	1.7594	1.3789	7.3776
P1	0.002			
P2		NS	NS	0.002

Segmental (%)	Control	Small dose	Mod. dose	Large dose
Mean	27.1000	29.3333	24.7500	20.500
St. Dev.	2.1318	11.1952	1.6690	4.2762
P1	0.050			
P2		NS	NS	0.048

Lymphocytes (%)	Control	Small dose	Mod. dose	Large dose
Mean	69.1000	64.5833	73.2500	76.0000
St. Dev.	1.8529	10.2820	1.5811	3.9279
P1	0.002			
P2		NS	NS	0.026

Monocytes (%)	Control	Small dose	Mod. dose	Large dose
Mean	2.400	1.7500	0.3750	1.8750
St. Dev.	0.6992	1.2154	0.2631	0.6409
P1	<0.001			
P2		NS	P<0.001	NS

Platelets (10 ³ /mm ³)	Control	Small dose	Mod. dose	Large dose
Mean	965.2000	1058.5000	1053.3750	808.5000
St. Dev.	340.2704	158.1728	71.5401	107.1141
P1	0.055			
P2		NS	NS	NS
Fibrinogen (gm/L)	Control	Small dose	Mod. dose	Large dose
Fibrinogen (gm/L) Mean	Control 2.3660	Small dose 2.9767	Mod. dose 1.8960	Large dose 3.5290
Fibrinogen (gm/L) Mean St. Dev.	Control 2.3660 0.3204	Small dose 2.9767 0.6394	Mod. dose 1.8960 0.3606	Large dose 3.5290 0.6448
Fibrinogen (gm/L) Mean St. Dev. P1	Control 2.3660 0.3204	Small dose 2.9767 0.6394 <0.	Mod. dose 1.8960 0.3606 001	Large dose 3.5290 0.6448









INF-γ (pg /ml)	Control	Small dose	Mod. dose	Large dose
Mean	108.2938	116.0400	120.8529	216.6857
St. Dev.	16.3355	9.6625	1.9348	93.1394
P1	0.001			
P2		NS	NS	P<0.001
TNF-α (pg/ml)	Control	Small dose	Mod. dose	Large dose
Mean	15.0556	10.3000	20.7286	23.4833
St. Dev.	2 7 4 9 7	4 0000	7 9406	E 044E
	2./40/	1.0000	7.0490	5.9115
P1	2.7407	1.0000 <0	.001	5.9115

MDA (μmol/L)	Control	Small dose	Mod. dose	Large dose
Mean	3.1139	5.2044	4.1240	3.7900
St. Dev.	0.06142	0.6188	0.1723	0.2654
P1	<0.001			
P2		P<0.001	P<0.001	P<0.001

LDH (U/L)	Control	Small dose	Mod. dose	Large dose
Mean	297.8250	197.3513	85.8362	1329.3850
St. Dev.	29.1004	85.5123	16.8045	282.7791
P1	<0.001			
P2		0.019	P<0.001	P<0.001

CPK (U/L)	Control	Small dose	Mod. dose	Large dose	
Mean	307.4656	165.2800	326.1188	607.4900	
St. Dev.	53.0163	45.4661	39.6316	269.1614	
P1	<0.001				
P2		0.003	NS	<0.001	
Act. (per 5 mins.)	Control	Small dose	Mod. dose	Large dose	
Mean	11.6667	17.5556	27.6250	1.5	
St. Dev.	4.0620	6.7103	3.5026	0.7071	
P1	<0.001				
P2		0.011	<0.001	<0.001	

	Capillary density (S.)			Capillary density (C.)	
Small d.	r	(P value)	Small d.	r	(P value)
RBCs	0.904*	(0.013)	C/F (C.)	0.994**	(<0.001)
INF-γ	-1.000**	(<0.001)	Perim. (C.)	-0.631	(0.050)
Moderate d.			Moderate d.		
C/F (C)	-0.894*	(0.016)	C/F (C.)	0.699*	(0.036)
Cap. dens. (C)	-0.851*	(0.032)	Cap. dens. (S)	-0.851*	(0.032)
			Activity	-0.822*	(0.012)
Large d.			Large d.		
LDH	-1.000**	-	C / F (C.)	0.867**	(0.003)
Perim. (S)	0.864*	(0.027)			
Eosin.%	0.903*	(0.014)			
Control			Control		
LDH	0.823*	(0.044)	C/F (C.)	0.841**	(0.002)
СРК	0.971**	(0.001)	ΤΝF- α	859**	(0.006)
Basoph. %	1.0000**	-			

Conclusion & Recommendation

Repeated medical ozone administration in smal dose can be encouraged as a "physiologica therapeutic endogenous angiogenic procedure' enhancing all the steps of the multifactoria angiogenic cascade.

Conclusion & Recommendation

Cont.

- From this aspect, medical ozone can be superior
- to the use of several angiogenic factors, which
- are liable to interfere with specific constitutional
- vascular endothelial growth factor (VEGF)
- isoforms function and can disturb the special
- pattern of distribution of its receptors.

